Skip to main content
Menu
US
Cell Counting and Image Cytometry

Tumor Spheroid Viability

Section
Celigo Applications
Celigo Applications
Cell Counting Method Selection
Cell Counting and Image Cytometry FAQs
Cell-based Assays for Bioprocessing
Cell-based Assays for Gene Therapy Development
Cellometer Applications
Modern Virology Assays
Sub Section
3D Cell Models
3D Cell Models
Assays for Virology Research
Brightfield Applications
Celigo Cell Counting Applications
Celigo Fluorescent Assays
Celigo Image Cytometer Direct Cell Counting Assays for Immunotherapy
Cell Line Development
Migration and Invasion Assays
iPSC Reprogramming
Topic
Tumor Spheroid Viability
Embryoid Bodies and Patient-Derived Organoids
3D Confrontation Assays
Growth Inhibition
Measure Apoptosis
Measure Migration onto extracellular matrix
Quantify Invasion into Matrigel
Tumor Spheroid Viability
Tumorsphere Formation & Clonogenic Survival

Detect and monitor viability of 3D tumor spheroids

  1. Directly image tumor spheroids in various microwell formats
  2. Non-invasive brightfield imaging allows the user to image the same plate over multiple days
  3. Perform a two-color fluorescent viability assay

Introduction

The Celigo image cytometer has been developed to fully automate imaging and analysis of tumorspheres. This automated morphometric analysis tool significantly reduces the time and effort needed to quantify key aspects of 3D spheres including size, growth, growth tracking over time and response to chemotherapeutics.

Monitor viability of 3D tumor spheroids

 3D tumor spheroids fluorescence viability setup

Experimental setup

3D cultures were treated with multiple drugs (17-AAG, Paclitaxel, TMZ or Doxorubicin) and stained for viability after 21 days.
Live / dead stains used were Calcein AM (green), Propidium Iodide (red) to measure live and dead cells on days 4, 7, 10, 14, and 17. Plates containing spheroids were imaged on Celigo image cytometer.

  • 17-AAG decreased sphere size and caused the most significant cell death
  • Paclitaxel decreased sphere size but maintained a significant number of live cells
  • Temozolomide caused no significant decrease in sphere size and did not cause cell death
  •  Doxorubicin decreased sphere size and caused significant cell death
     
 3D tumor spheroids fluorescence viability

Multi-drug viability 3D assay

Multidrug 3D tumor spheroids viability assay

Spheroid diameter (black) and total live fluorescent intensity (green) after drug treatment.

3D tumor spheroids treated at different drug concentrations and stained with propidium iodide

3D tumor spheroids control

Control

3D tumor spheroid medium drug dose

Medium drug dose

 3D tumor spheroid high drug dose

High drug dose

Measuring viability 3D spheroids with morphological differences

3D spheroid morphological differences 1
3D spheroid morphological differences 2
3D spheroid morphological differences 3
3D spheroid morphological differences 4
 3D spheroid morphological differences 5
3D spheroid morphological differences 6
 3D spheroid morphological differences 7
3D spheroid morphological differences 8
3D spheroid morphological differences 12
3D spheroid morphological differences 11
3D spheroid morphological differences 10
3D spheroid morphological differences 9
3D spheroid morphological differences 13
3D spheroid morphological differences 14
3D spheroid morphological differences 15
3D spheroid morphological differences 16

3D tumor spheroids treated with various compounds and stained with calcein-AM and PI

Treated 3D tumor spheroids 2
Treated 3D tumor spheroids 1

For research use only. Not for use in diagnostic procedures.

ON THIS PAGE